Solventum Lifts 2026 Earnings Outlook To $7.20–$7.30 As Advance Orders Reverse

The healthcare supplier completed its business-system transitions, while wound care and software sales grew and dental sales fell.

Share
Solventum Lifts 2026 Earnings Outlook To $7.20–$7.30 As Advance Orders Reverse

Solventum, which makes medical and dental products and healthcare software, raised its 2026 adjusted earnings outlook to $7.20–$7.30 per share from $7.10–$7.20 Thursday, despite lower third-quarter sales. Customers’ advance orders ahead of a business-management system switch reversed during the quarter, an expected effect the company said accounted for the sales decline excluding currency movements, acquisitions and divestitures.

Advance Orders Distort The Quarter

Third-quarter revenue was $1,949 million against $2,096 million a year earlier: down 7.0% as reported, or 2.8% excluding currency effects, acquisitions and divestitures. The reversal of orders placed in the second quarter reduced third-quarter growth on that latter basis by 6.30 percentage points.

Adjusted earnings reached $1.45 per share, versus $1.50 a year earlier. Adjusted operating margin was 19.9%, compared with 20.6%; management attributed that decline chiefly to the advance-order reversal. Both standard-accounting and adjusted gross margins improved, with product mix, portfolio changes and savings outweighing part of the pressure from inflation and tariffs.

The unaudited results showed a $12 million loss, or $0.07 per share, versus $1,266 million in profit a year earlier. The comparison includes a $1,518 million gain from the September 2025 sale of purification and filtration operations. That gain and higher restructuring costs chiefly explained the deterioration in standard-accounting operating profitability, the company said.

SOLV shares jumped about 6% to $92.04 in Friday trading.

Wound Care Grows, Dental Retreats

Solventum’s MedSurg business supplies wound treatments, infection-prevention products and surgical equipment. Its other segments sell dental and orthodontic products and software for healthcare documentation, coding and speech recognition.

Advanced wound care sales reached $528 million, versus $485 million a year earlier. Reported growth was 8.9%, while growth excluding currency effects and deals was 1.5%; the acquisition contribution included Acera, bought in December 2025. Infection Prevention and Surgical Solutions sales fell to $683 million from $722 million, leaving MedSurg revenue at $1,211 million against $1,206 million.

Dental Solutions revenue declined to $317 million from $340 million. Health Information Systems moved the other way, with sales of $356 million versus $345 million and operating margin of 41.7% against 38.8%.

The FDA cleared the combined use of Restrata and V.A.C. Therapy, adding an integration milestone for Acera Surgical’s technology within Solventum’s wound-care portfolio.

System Switches Done, Cash Outlook Unchanged

Solventum finished its business-management system transitions and exited approximately 90% of its service agreements with 3M. Bryan Hanson, Solventum’s chief executive officer, said, “With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins.”

Management expects full-year sales growth excluding currency effects, acquisitions and divestitures toward the high end of 2.5%–3.0%. For the first nine months, that measure grew 2.9%, even as reported sales fell 2.6% to $6,165 million. Adjusted earnings for that period were $5.48 per share, up from $4.53.

Third-quarter operating cash flow was $177 million, versus $75 million a year earlier. Free cash flow—operating cash remaining after capital spending—was $97 million, compared with negative $22 million. A tariff refund helped cash generation exceed management’s expectations.

Solventum retained its full-year free-cash-flow forecast of $200 million–$300 million; free cash flow for the first nine months remained negative $32 million.

Sources

More on Solventum

All Solventum (SOLV) coverage →